Clinical Report: Tiny Heart Samples, Detailed Protein Data
Overview
A new method for extracting phospholamban from cardiac tissue has been developed, reducing the required tissue amount from 10 mg to 1 mg while maintaining analytical performance.
Background
Phospholamban is a critical membrane protein involved in calcium regulation and heart contraction, with alterations linked to heart failure and cardiomyopathies. Traditional methods for studying this protein are cumbersome and inefficient for small tissue samples.
Data Highlights
| Parameter | Value |
|---|---|
| Tissue Amount | 1 mg |
| Total Protein Yield | 30 to 60 µg |
| Sequence Coverage | 71% |
Key Findings
- A simplified one-pot extraction method for phospholamban was developed.
- The method reduced the tissue requirement from 10 mg to 1 mg without compromising analytical performance.
- Phosphorylation sites identified were Ser16 and Thr17.
- The method produced comparable measurements of phospholamban phosphorylation to conventional methods.
Clinical Implications
This new extraction method allows for detailed analysis of cardiac proteins using minimal tissue.
Conclusion
The development of this extraction method represents a significant advancement in the analysis of phospholamban.
Related Resources & Content
- The Analytical Scientist, 2019 -- Getting to the Heart of the Proteforms
- Basic Research in Cardiology, 2014 -- Expression and Genetic Variants of FHL2 in Hypertrophic Cardiomyopathy
- Basic Research in Cardiology, 2017 -- Cardiac Odorant Receptor Influence on Myocardial Function by Medium-Chain Fatty Acids
- 2023 ESC Guidelines for the management of cardiomyopathies | European Heart Journal | Oxford Academic
- Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.
- Basic Research in Cardiology — LncRNA LncHrt supports cardiac metabolic balance and heart performance through the modulation of the LKB1-AMPK signaling pathway
- 2023 ESC Guidelines for the management of cardiomyopathies | European Heart Journal | Oxford Academic
- Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.
Based on findings from:
Tiny Heart Samples, Detailed Protein Data
The Analytical Scientist, 2026.
https://theanalyticalscientist.com/issues/2026/articles/september/tiny-heart-samples-detailed-protein-data/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
